Associated Papers
Suppression of NRAS-mutant melanoma growth with NRAS-targeting Antisense Oligonucleotide treatment reveals therapeutically relevant kinase co-dependencies.
Feichtenschlager V et al.
Communications Medicine, 2025
40473796 (PubMed )
Supplement: 43856_2025_932_MOESM3_ESM.xlsx › CRISPR
Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows.
Sobahy TM et al.
Bmc Medical Genomics, 2022
35468810 (PubMed )
Supplement: 12920_2022_1235_MOESM2_ESM.xlsx › Sheet1
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
33226070 (PubMed )
Supplement: btaa972_supplementary_data.zip › RAS_Manuscript_RMarkdown.tar.gz › RAS_Manuscript1.Revised › RAS_Variants_Scores.xlsx › Sheet1
LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.
Melloni GE et al.
Bmc Bioinformatics, 2016
26860319 (PubMed )
Supplement: 12859_2016_935_MOESM2_ESM.xlsx › Table_S5
A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.
Xia J et al.
Molecular Cancer Therapeutics, 2014
Select a paper to view details